Analysis of HCRTR2, GNB3, and ADH4 Gene Polymorphisms in a Southeastern European Caucasian Cluster Headache Population

• Published in: Journal of molecular neuroscience 2020-03, Vol.70 (3), p.467-474
• Main Authors: Papasavva, Maria, Katsarou, Martha-Spyridoula, Vikelis, Michail, Mitropoulou, Euthymia, Dermitzakis, Emmanouil V., Papakonstantinou, Stylianos, Arvaniti, Chryssa, Mitsikostas, Dimos-Dimitrios, Gozes, Illana, Tsatsakis, Aristides M., Drakoulis, Nikolaos
• Format: Article
• Language: English
• Subjects: ADH4 protein; Adult; Aged; Alcohol Dehydrogenase - genetics; Alleles; Biomedical and Life Sciences; Biomedicine; Cell Biology; Cluster Headache - genetics; Clusters; Deoxyribonucleic acid; DNA; Female; Gene distribution; Gene Frequency; Headache; Headaches; Heterotrimeric GTP-Binding Proteins - genetics; Humans; Male; Middle Aged; Migraine; Neurochemistry; Neurology; Neurosciences; Orexin receptors; Orexin Receptors - genetics; Polymorphism; Polymorphism, Single Nucleotide; Population; Population studies; Proteomics; Signal transduction; Statistical analysis
• ISSN: 0895-8696; 1559-1166
• DOI: 10.1007/s12031-019-01439-0

Studies point to an increased hereditary risk of cluster headache. HCRTR2 gene rs2653349 and ADH4 gene rs1800759 polymorphisms have been associated with cluster headache susceptibility. Also, GNB3 rs5443 polymorphism, associated with increased signal transduction via GPCRs, seems to influence triptan treatment response. DNA from 114 cluster headache patients and 570 non-related controls, representing a general Southeastern European Caucasian (SEC) population, was extracted from buccal swabs and genotyped using real-time PCR. Gene distribution for the rs2653349 was GG = 79.8%, GA = 18.4%, and AA = 1.8% for patients and GG = 79.1%, GA = 19.1%, and AA = 1.8% for controls. The frequency of the mutated A allele was 11.0% for patients and 11.3% for controls. The frequencies for rs5443 were CC = 44.7%, CT = 44.7%, and TT = 10.5% for patients and CC = 43.9%, CT = 42.6%, and TT = 13.5% for controls. The frequency of the mutated T allele was 32.9% for patients and 34.8% for controls. A 2.7-fold more frequent appearance of the mutated T allele was observed in patients with better triptan treatment response, although not statistically significant. For rs1800759, the frequencies were CC = 36.0%, CA = 43.0%, and AA = 21.0% for patients and CC = 34.0%, CA = 50.2%, and AA = 15.8% for controls. The frequency of the mutated A allele was 42.5% and 40.9% for patients and controls, respectively. The mutated T allele of GNB3 rs5443 polymorphism was more prevalent in patients with better triptan treatment response, indicating a possible trend of association between this polymorphism and triptan treatment response in SEC population. According to our observation, no association of HCRTR2 rs2653349 and ADH4 rs1800759 polymorphisms and cluster headache in SEC population could be documented.